Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2006

01-06-2006 | Original Article

Modification of accessory molecule signaling

Author: Mary K. Crow

Published in: Seminars in Immunopathology | Issue 4/2006

Login to get access

Abstract

The concept of costimulation, the requirement for an independent accessory cellular activation signal that supplements the signal delivered to a lymphocyte by antigen, has been a focal point of progress in understanding the regulation of the immune system. While considerable attention has been directed to new developments related to the activation of cells of the innate immune system through Toll-like receptors, resulting in the production of soluble mediators, augmented expression of cell surface costimulatory molecules on antigen-presenting cells is arguably the most significant early outcome of immune system activation. It is those cell surface molecules that provide the essential afferent costimulatory signals to T cells of the adaptive immune response. Once fully activated, T cells express their own cell surface accessory molecules that permit those T cells to instruct interacting B cells, macrophages, and dendritic cells to further implement an effective immune response. Significantly for patients with autoimmune diseases, the manipulation of costimulatory signals represents a rational and effective approach to modulating the chronic immune system activation that characterizes those diseases. Further elucidation of the complexities of members of the accessory molecule families and their functions should lead to an ever greater capacity for therapeutic modulation of the immune response in autoimmune and inflammatory diseases.
Literature
1.
Beutler B (2005) The Toll-like receptors: analysis by forward genetic methods. Immunogenetics 57:385–392PubMedCrossRef
2.
Ronnblom L, Eloranta ML, Alm GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54:408–420PubMedCrossRef
3.
Crow MK, Kirou KA (2004) Interferon-alpha in systemic lupus erythematosus. Curr Opin Rheumatol 16:541–547PubMedCrossRef
4.
Edelman GM (1987) CAMs and Igs: cell adhesion and the evolutionary origins of immunity. Immunol Rev 100:11–45PubMedCrossRef
5.
Coyle AJ, Gutierrez-Ramos JC (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2:203–209PubMedCrossRef
6.
Frauwirth KA, Thompson CB (2002) Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109:295–299PubMed
7.
Gonzalo JA, Delaney T, Corcoran J, Goodearl A, Gutierrez-Ramos JC, Coyle AJ (2001) Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J Immunol 166:1–5PubMed
8.
Peggs KS, Allison JP (2005) Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 130:809–824PubMedCrossRef
9.
10.
Shapiro L, Scherer PE (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8:335–338PubMedCrossRef
11.
Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12:881–922PubMedCrossRef
12.
13.
Bretscher P (1992) The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 13:74–76PubMedCrossRef
14.
Crow MK, Kunkel HG (1982) Human dendritic cells: major stimulators of the autologous and allogeneic mixed leucocyte reactions. Clin Exp Immunol 49:338–346PubMed
15.
van Voorhis WC, Valinsky J, Hoffman E, Luban J, Hair LS, Steinman RM (1983) Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med 158:174–191PubMedCrossRef
16.
Crow MK, Kunkel HG (1985) Activated B lymphocytes: stimulators of an augmented autologous mixed leukocyte reaction. Cell Immunol 90:555–568PubMedCrossRef
17.
18.
Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hunig T, Kerkau T, Gold R (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202:445–455PubMedCrossRef
19.
Beyersdorf N, Hanke T, Kerkau T, Hunig T (2006) CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun Rev 5:40–45PubMedCrossRef
20.
Dabbagh K, Dahl ME, Stepick-Biek P, Lewis DB (2002) Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J Immunol 168:4524–4530PubMed
21.
Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1:147–153PubMedCrossRef
22.
Martens PB, Goronzy JJ, Schaid D, Weyand CM (1997) Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 40:1106–1114PubMedCrossRef
23.
Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, Manning S, Nguyen T, Burwell T, Schneider H, Gonzalo JA, Gosselin M, Owen LR, Rudd CE, Gutierrez-Ramos JC (2000) The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13:95–105PubMedCrossRef
24.
Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA (1999) ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397:263–266PubMedCrossRef
25.
Okazaki T, Iwai Y, Honjo T (2002) New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14:779–782PubMedCrossRef
26.
Wallin JJ, Liang L, Bakardjiev A, Sha WC (2001) Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J Immunol 167:132–139PubMed
27.
Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K (2002) Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14:275–286PubMedCrossRef
28.
Linton PJ, Bautista B, Biederman E, Bradley ES, Harbertson J, Kondrack RM, Padrick RC, Bradley LM (2003) Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med 197:875–883PubMedCrossRef
29.
Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB (1989) Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339–343PubMedCrossRef
30.
de Boer M, Kasran A, Kwekkeboom J, Walter H, Vandenberghe P, Ceuppens JL (1993) Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol 23:3120–3125PubMedCrossRef
31.
Smith KM, Brewer JM, Webb P, Coyle AJ, Gutierrez-Ramos C, Garside P (2003) Inducible costimulatory molecule-B7-related protein 1 interactions are important for the clonal expansion and B cell helper functions of naive, Th1, and Th2 T cells. J Immunol 170:2310–2315PubMed
32.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034PubMedCrossRef
33.
Greenwald RJ, Latchman YE, Sharpe AH (2002) Negative co-receptors on lymphocytes. Curr Opin Immunol 14:391–396PubMedCrossRef
34.
Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA, Sharpe AH (2002) CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 32:366–373PubMedCrossRef
35.
Riley JL, June CH (2005) The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105:13–21PubMedCrossRef
36.
Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201–210PubMedCrossRef
37.
McAdam AJ, Greenwald RJ, Levin MA, Chernova T, Malenkovich N, Ling V, Freeman GJ, Sharpe AH (2001) ICOS is critical for CD40-mediated antibody class switching. Nature 409:102–105PubMedCrossRef
38.
Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP (1996) Control of the complement system. Adv Immunol 61:201–283PubMedCrossRef
39.
Mackay F, Kalled SL (2002) TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol 14:783–790PubMedCrossRef
40.
Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK et al (1993) CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259:990–993PubMedCrossRef
41.
Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L (1992) Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 175:1091–1101PubMedCrossRef
42.
Klaus SJ, Pinchuk LM, Ochs HD, Law CL, Fanslow WC, Armitage RJ, Clark EA (1994) Costimulation through CD28 enhances T cell-dependent B cell activation via CD40–CD40L interaction. J Immunol 152:5643–5652PubMed
43.
Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE, Covey LR, Lee JJ, Rothman P, Chess L (1994) T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol 152:2163–2171PubMed
44.
Shapira SK, Vercelli D, Jabara HH, Fu SM, Geha RS (1992) Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J Exp Med 175:289–292PubMedCrossRef
45.
Splawski JB, Fu SM, Lipsky PE (1993) Immunoregulatory role of CD40 in human B cell differentiation. J Immunol 150:1276–1285PubMed
46.
Schattner EJ, Elkon KB, Yoo DH, Tumang J, Krammer PH, Crow MK, Friedman SM (1995) CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 182:1557–1565PubMedCrossRef
47.
Caux C, Massacrier C, Vanbervliet B, Dubois B, van Kooten C, Durand I, Banchereau J (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263–1272PubMedCrossRef
48.
Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK (1993) CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178:669–674PubMedCrossRef
49.
Kobayashi N, Nagumo H, Agematsu K (2002) IL-10 enhances B-cell IgE synthesis by promoting differentiation into plasma cells, a process that is inhibited by CD27/CD70 interaction. Clin Exp Immunol 129:446–452PubMedCrossRef
50.
Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM (2002) Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 277:575–585PubMedCrossRef
51.
Cerutti A, Schaffer A, Goodwin RG, Shah S, Zan H, Ely S, Casali P (2000) Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J Immunol 165:786–794PubMed
52.
Pollard KM, Hultman P, Kono DH (2003) Using single-gene deletions to identify checkpoints in the progression of systemic autoimmunity. Ann N Y Acad Sci 987:236–239PubMedCrossRef
53.
Castigli E, Alt FW, Davidson L, Bottaro A, Mizoguchi E, Bhan AK, Geha RS (1994) CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 91:12135–12139PubMedCrossRef
54.
Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA (2001) ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409:97–101PubMedCrossRef
55.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–547PubMedCrossRef
56.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988PubMedCrossRef
57.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151PubMedCrossRef
58.
Chu JL, Drappa J, Parnassa A, Elkon KB (1993) The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 178:723–730PubMedCrossRef
59.
Hudson LL, Rocca K, Song YW, Pandey JP (2002) CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111:452–455PubMedCrossRef
60.
Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063–2073PubMedCrossRef
61.
Koshy M, Berger D, Crow MK (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98:826–837PubMedCrossRef
62.
Mohan C, Shi Y, Laman JD, Datta SK (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154:1470–1480PubMed
63.
Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK (1999) Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42:871–881PubMedCrossRef
64.
Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, Hashimoto H, Kipps TJ (1999) The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 104:947–955PubMedCrossRef
65.
Bijl M, Horst G, Limburg PC, Kallenberg CG (2001) Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 60:523–526PubMedCrossRef
66.
Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666–669PubMedCrossRef
67.
Pullmann R Jr, Lukac J, Skerenova M, Rovensky J, Hybenova J, Melus V, Celec S, Pullmann R, Hyrdel R (1999) Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin Exp Rheumatol 17:725–729PubMed
68.
Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS, Krueger JG (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192:681–694PubMedCrossRef
69.
Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D (1997) Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 159:3104–3108PubMed
70.
Emery P (2003) The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 12:673–681PubMedCrossRef
71.
Bluestone JA, St Clair EW, Turka LA (2006) CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 24:233–238PubMedCrossRef
72.
Moreland LW, Alten R, van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470–1479PubMedCrossRef
73.
Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ (1995) Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 96:987–993PubMedCrossRef
74.
Wang X, Huang W, Mihara M, Sinha J, Davidson A (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168:2046–2053PubMed
75.
Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133–1145PubMed
76.
Kosuge H, Suzuki J, Gotoh R, Koga N, Ito H, Isobe M, Inobe M, Uede T (2003) Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75:1374–1379PubMedCrossRef
77.
Foell J, Strahotin S, O’Neil SP, McCausland MM, Suwyn C, Haber M, Chander PN, Bapat AS, Yan XJ, Chiorazzi N, Hoffmann MK, Mittler RS (2003) CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 111:1505–1518PubMed
78.
Kalled SL, Cutler AH, Datta SK, Thomas DW (1998) Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 160:2158–2165PubMed
79.
Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:3251–3258PubMedCrossRef
80.
Huang W, Sinha J, Newman J, Reddy B, Budhai L, Furie R, Vaishnaw A, Davidson A (2002) The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 46:1554–1562PubMedCrossRef
81.
Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206–213PubMedCrossRef
Metadata
Title
Modification of accessory molecule signaling
Author
Mary K. Crow
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 4/2006
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-006-0018-3

Other articles of this Issue 4/2006

Seminars in Immunopathology 4/2006 Go to the issue

Introduction

Biological immunomodulators

Original Article

Interleukin-12 to interleukin ‘infinity’: the rationale for future therapeutic cytokine targeting

Original Article

Disturbances in placental immunology: ready for therapeutic interventions?

Original Article

Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases

Original Article

Hereditary auto-inflammatory disorders and biologics

Erratum

Complement C2 receptor inhibitor trispanning: from man to schistosome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits